Research appointment pre-doc
06/MEDS-02 - Experimental Medicine, Pathophysiology And Clinical Pathology
Uni. Brescia
Posted on: 16/11/2026 Deadline: 01/12/2026

FGF/FGFR system inhibition as a therapeutic strategy for high-risk and chemoresistant medulloblastoma

Medulloblastoma (MB) is the most common malignant pediatric brain tumor. MB-SHH tumors with TP53 mutation and Group 3 MB, often characterized by high aggressiveness, dissemination and treatment resistance, require novel targeted strategies. The project will investigate the role of FGF/FGFR signaling and the therapeutic potential of its blockade using clinically available FGFR inhibitors and next-generation FGF-trap molecules. Murine and human cell models, primary cells, patient-derived xenograft organoids and orthotopic in vivo models will be used. Effects on tumor growth, cell signaling and the tumor microenvironment will be characterized, together with the efficacy of combination treatments with conventional and innovative chemotherapies. Particular attention will be given to chemoresistant models to determine whether FGF/FGFR targeting can overcome resistance and prevent relapse.

Selection process

Public notice for the direct approval of a research position pursuant to Article 22-ter, paragraph 4, of Law No. 240/2010, a.d. MEDS-02/A “Experimental Medicine and Pathophysiology" The evaluation criteria are established in the call; a master's degree obtained no more than six years ago is required; knowledge of Italian and English is required. The professional expertise considered preferable for the purposes of the intended collaboration will relate to experience in cellular biology, molecular biology, the study of the tumor microenvironment, and in vivo models in experimental oncology.
Back to jobs